Salvacyl 11,25 mg pulver og solvens til depotinjektionsvæske, suspension डेनमार्क - डेनिश - Lægemiddelstyrelsen (Danish Medicines Agency)

salvacyl 11,25 mg pulver og solvens til depotinjektionsvæske, suspension

institut produits synthése (ipsen) ab - triptorelinpamoat - pulver og solvens til depotinjektionsvæske, suspension - 11,25 mg

Xtandi यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamide - prostatiske neoplasmer - endokrine terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Erleada यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

erleada

janssen-cilag international nv - apalutamide - prostatiske neoplasmer - endokrine terapi - erleada er anført:i voksne mænd til behandling af ikke-metastatisk kastration resistent prostatakræft (nmcrpc), som er i høj risiko for at udvikle metastatisk sygdom. hos voksne mænd til behandling af metastatisk hormon-følsomme prostatakræft (mhspc) i kombination med androgen deprivation terapi (adt).

Akeega यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

akeega

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatic neoplasmer, kastration-resistent - antineoplastiske midler - treatment of adult patients with prostate cancer.

Elonva यूरोपीय संघ - डेनिश - EMA (European Medicines Agency)

elonva

n.v. organon - corifollitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - køn hormoner og modulatorer af den genitale system, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).